Compare Stocks: GLUE, DYN, CELC, and ELVN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CELC Celcuity	$88.44 -5.1%	$94.64	$44.42 ▼ $151.02	$4.33B	0.2	747,478 shs	610,269 shs
DYN Dyne Therapeutics	$25.07 -3.9%	$24.37	$11.92 ▼ $27.31	$4.68B	1.07	1.76 million shs	1.19 million shs
ELVN Enliven Therapeutics	$57.86 -4.4%	$54.62	$14.78 ▼ $62.32	$4.24B	0.27	1.06 million shs	584,978 shs
GLUE Monte Rosa Therapeutics	$13.38 -6.6%	$19.72	$4.60 ▼ $25.77	$1.14B	1.59	1.52 million shs	884,550 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CELC Celcuity	0.00%	-5.44%	+0.91%	-33.44%	+77.02%
DYN Dyne Therapeutics	0.00%	-3.95%	-2.57%	+29.69%	+83.80%
ELVN Enliven Therapeutics	0.00%	-3.28%	+7.25%	+46.22%	+179.79%
GLUE Monte Rosa Therapeutics	0.00%	-6.43%	-41.01%	-32.12%	+186.51%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CELC Celcuity	$88.44 -5.1%	$94.64	$44.42 ▼ $151.02	$4.33B	0.2	747,478 shs	610,269 shs
DYN Dyne Therapeutics	$25.07 -3.9%	$24.37	$11.92 ▼ $27.31	$4.68B	1.07	1.76 million shs	1.19 million shs
ELVN Enliven Therapeutics	$57.86 -4.4%	$54.62	$14.78 ▼ $62.32	$4.24B	0.27	1.06 million shs	584,978 shs
GLUE Monte Rosa Therapeutics	$13.38 -6.6%	$19.72	$4.60 ▼ $25.77	$1.14B	1.59	1.52 million shs	884,550 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CELC Celcuity	0.00%	-5.44%	+0.91%	-33.44%	+77.02%
DYN Dyne Therapeutics	0.00%	-3.95%	-2.57%	+29.69%	+83.80%
ELVN Enliven Therapeutics	0.00%	-3.28%	+7.25%	+46.22%	+179.79%
GLUE Monte Rosa Therapeutics	0.00%	-6.43%	-41.01%	-32.12%	+186.51%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CELC Celcuity	2.82	Moderate Buy	$154.55	74.75% Upside
DYN Dyne Therapeutics	2.87	Moderate Buy	$34.42	37.28% Upside
ELVN Enliven Therapeutics	2.78	Moderate Buy	$75.00	29.62% Upside
GLUE Monte Rosa Therapeutics	2.78	Moderate Buy	$28.50	113.00% Upside

Current Analyst Ratings Breakdown

Latest GLUE, DYN, CELC, and ELVN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2026	GLUE Monte Rosa Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$28.00
8/24/2026	GLUE Monte Rosa Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/18/2026	ELVN Enliven Therapeutics	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
8/18/2026	ELVN Enliven Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$78.00
8/18/2026	ELVN Enliven Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$62.00 ➝ $73.00
8/17/2026	CELC Celcuity	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$165.00 ➝ $175.00
8/17/2026	DYN Dyne Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$50.00
8/17/2026	CELC Celcuity	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/17/2026	CELC Celcuity	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$177.00
8/14/2026	CELC Celcuity	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$155.00
8/14/2026	CELC Celcuity	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$175.00 ➝ $150.00

(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CELC Celcuity	N/A	N/A	N/A	N/A	($0.26) per share	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$3.76 per share	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$12.22 per share	N/A
GLUE Monte Rosa Therapeutics	$123.67M	9.23	N/A	N/A	$5.71 per share	2.34

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CELC Celcuity	-$177.04M	-$4.30	N/A	N/A	N/A	N/A	-350.78%	-41.54%	11/11/2026 (Estimated)
DYN Dyne Therapeutics	-$446.21M	-$3.33	N/A	N/A	N/A	N/A	-64.30%	-50.33%	11/4/2026 (Estimated)
ELVN Enliven Therapeutics	-$103.69M	-$1.67	N/A	N/A	N/A	N/A	-18.55%	-18.09%	11/11/2026 (Estimated)
GLUE Monte Rosa Therapeutics	-$38.63M	-$1.76	N/A	N/A	N/A	-560.85%	-43.31%	-27.59%	11/5/2026 (Estimated)

Latest GLUE, DYN, CELC, and ELVN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CELC Celcuity	-$1.16	-$1.44	-$0.28	-$1.44	$4.42 million	N/A
8/6/2026	Q2 2026	GLUE Monte Rosa Therapeutics	-$0.3805	-$0.43	-$0.0495	-$0.43	$12.91 million	$8.97 million
8/5/2026	Q2 2026	ELVN Enliven Therapeutics	-$0.3872	-$0.49	-$0.1028	-$0.49	N/A	N/A
7/30/2026	Q2 2026	DYN Dyne Therapeutics	-$0.7488	-$1.08	-$0.3312	-$1.08	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CELC Celcuity	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A
GLUE Monte Rosa Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CELC Celcuity	6.04	8.93	8.93
DYN Dyne Therapeutics	0.28	12.02	12.02
ELVN Enliven Therapeutics	N/A	64.07	64.07
GLUE Monte Rosa Therapeutics	N/A	10.58	10.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CELC Celcuity	63.33%
DYN Dyne Therapeutics	96.68%
ELVN Enliven Therapeutics	95.08%
GLUE Monte Rosa Therapeutics	79.96%

Insider Ownership

Company	Insider Ownership
CELC Celcuity	13.33%
DYN Dyne Therapeutics	9.46%
ELVN Enliven Therapeutics	3.00%
GLUE Monte Rosa Therapeutics	6.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CELC Celcuity	40	48.93 million	42.41 million	Optionable
DYN Dyne Therapeutics	100	186.75 million	169.08 million	Optionable
ELVN Enliven Therapeutics	50	73.27 million	71.07 million	Optionable
GLUE Monte Rosa Therapeutics	90	85.31 million	79.85 million	Optionable

GLUE, DYN, CELC, and ELVN Headlines

Recent News About These Companies

Empowered Funds LLC Purchases Shares of 329,266 Monte Rosa Therapeutics, Inc. $GLUE

August 30 at 4:01 AM | marketbeat.com

Nantahala Capital Management LLC Buys Shares of 651,993 Monte Rosa Therapeutics, Inc. $GLUE

August 29 at 6:37 AM | marketbeat.com

Jupiter Topco LLC Makes New $25.96 Million Investment in Monte Rosa Therapeutics, Inc. $GLUE

August 29 at 5:44 AM | marketbeat.com

Deutsche Bank AG Invests $1.82 Million in Monte Rosa Therapeutics, Inc. $GLUE

August 29 at 4:08 AM | marketbeat.com

BlackRock Inc. Purchases New Shares in Monte Rosa Therapeutics, Inc. $GLUE

August 29 at 3:37 AM | marketbeat.com

Monte Rosa Therapeutics (NASDAQ:GLUE) Upgraded at TD Cowen

August 27 at 4:51 AM | americanbankingnews.com

615,287 Shares in Monte Rosa Therapeutics, Inc. $GLUE Acquired by Boone Capital Management LLC

August 27 at 4:16 AM | marketbeat.com

Bank of America Corp DE Raises Stock Position in Monte Rosa Therapeutics, Inc. $GLUE

August 27 at 3:27 AM | marketbeat.com

Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price Up 7.4% on Analyst Upgrade

August 27 at 1:51 AM | americanbankingnews.com

Guggenheim Reiterates Buy Rating for Monte Rosa Therapeutics (NASDAQ:GLUE)

August 27 at 1:13 AM | americanbankingnews.com

ADAR1 Capital Management LLC Buys Shares of 216,752 Monte Rosa Therapeutics, Inc. $GLUE

August 26, 2026 | marketbeat.com

Monte Rosa Therapeutics (NASDAQ:GLUE) Trading 7.4% Higher on Analyst Upgrade

August 25, 2026 | marketbeat.com

Guggenheim Reaffirms "Buy" Rating for Monte Rosa Therapeutics (NASDAQ:GLUE)

August 25, 2026 | marketbeat.com

Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Rating Upgraded by TD Cowen

August 25, 2026 | marketbeat.com

Monte Rosa Therapeutics Doses First Patient in Phase 2 Prostate Cancer Study

August 24, 2026 | finance.yahoo.com

Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic...

August 24, 2026 | markets.businessinsider.com

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of "Moderate Buy" by Brokerages

August 24, 2026 | marketbeat.com

Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer

August 24, 2026 | globenewswire.com

Alphabet Inc. Buys Shares of 372,474 Monte Rosa Therapeutics, Inc. $GLUE

August 18, 2026 | marketbeat.com

Monte Rosa Therapeutics (NASDAQ:GLUE) Announces Earnings Results

August 8, 2026 | marketbeat.com

The Manufacturers Life Insurance Company Raises Stake in Monte Rosa Therapeutics, Inc. $GLUE

August 8, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GLUE, DYN, CELC, and ELVN Company Descriptions

Celcuity NASDAQ:CELC

$88.44 -4.80 (-5.15%)

As of 08/28/2026 04:00 PM Eastern

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Dyne Therapeutics NASDAQ:DYN

$25.07 -1.02 (-3.91%)

As of 08/28/2026 04:00 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Enliven Therapeutics NASDAQ:ELVN

$57.86 -2.64 (-4.36%)

As of 08/28/2026 04:00 PM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Monte Rosa Therapeutics NASDAQ:GLUE

$13.38 -0.94 (-6.56%)

As of 08/28/2026 04:00 PM Eastern

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GLUE, DYN, CELC, and ELVN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GLUE, DYN, CELC, and ELVN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GLUE, DYN, CELC, and ELVN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GLUE, DYN, CELC, and ELVN Company Descriptions

Celcuity NASDAQ:CELC

Dyne Therapeutics NASDAQ:DYN

Enliven Therapeutics NASDAQ:ELVN

Monte Rosa Therapeutics NASDAQ:GLUE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GLUE, DYN, CELC, and ELVN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GLUE, DYN, CELC, and ELVN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GLUE, DYN, CELC, and ELVN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GLUE, DYN, CELC, and ELVN Company Descriptions

Celcuity NASDAQ:CELC

Dyne Therapeutics NASDAQ:DYN

Enliven Therapeutics NASDAQ:ELVN

Monte Rosa Therapeutics NASDAQ:GLUE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools